$ABMD

TransMedics has seen a remarkable increase of 104% in stock value over the past year, primarily due to advancements in its organ transplant technology. Investors are debating whether it's still a good opportunity to buy the stock ahead of potential growth expected in 2026. Analysts suggest that although the stock has performed well, caution is advised due to market volatility and competition within the biotechnology sector. The rising demand for organ transplants and innovative solutions in the health tech space may continue to drive the stock price higher. Overall, there are mixed views on the sustainability of this momentum moving forward.